Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCI | P41743 | 1/20 | 0.49 |
| ▸ | MAP2K4 | P45985 | 2/20 | 0.43 |
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.42 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.42 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.42 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.42 |
| ▸ | CDK8 | P49336 | 1/20 | 0.41 |
| ▸ | BRAF | P15056 | 1/20 | 0.41 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.39 |
| ▸ | FYN | P06241 | 2/20 | 0.38 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.37 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.37 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.37 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.36 |
| ▸ | MGLL | Q99685 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1557945 | 0.83 | PIM1 (0.34) | PRKCI | |
| SCHEMBL17548483 | 0.83 | CYP4F2 (0.38) | PRKCIPARP1 | |
| SCHEMBL5950532 | 0.83 | PIM1 (0.31) | PRKCI | |
| SCHEMBL2233428 | 0.83 | TSHR (0.34) | PRKCIMAP2K4 | |
| SCHEMBL2056403 | 0.83 | NOTUM (0.47) | MAP2K4FGFR1MGLL | |
| SCHEMBL6740112 | 0.83 | NOTUM (0.34) | PRKCIPARP1BRAF | |
| SCHEMBL7810819 | 0.83 | CDK8 (0.41) | FGFR1CDK8ENPP2CHEK1 | |
| SCHEMBL6963004 | 0.82 | MAOA (0.41) | — | |
| SCHEMBL6958334 | 0.82 | HRH3 (0.41) | ACMSD | |
| Hydrochloric Acid SCHEMBL7808326 | 0.82 | CDK8 (0.40) | FGFR1CDK8ENPP2CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11993729-B2 | Chemical mechanical polishing composition | BASF SE (DE) | 2024-05-28 | — | — | US | disclosed |
| EP-3714012-B1 | CHEMICAL MECHANICAL POLISHING COMPOSITION | BASF SE (DE) | 2023-01-11 | — | — | EP | disclosed |
| CN-107922787-B | Use of Chemical Mechanical Polishing (CMP) compositions for polishing cobalt-containing substrates | 巴斯夫欧洲公司 | 2021-06-29 | — | — | CN | disclosed |
| US-20210102093-A1 | USE OF A CHEMICAL MECHANICAL POLISHING (CMP) COMPOSITION FOR POLISHING OF COBALT COMPRISING SUBSTRATES | BASF SE (DE) | 2021-04-08 | — | — | US | disclosed |
| US-10899945-B2 | Use of a chemical mechanical polishing (CMP) composition for polishing of cobalt comprising substrates | BASF SE (DE) | 2021-01-26 | — | — | US | disclosed |
| EP-3714012-A1 | CHEMICAL MECHANICAL POLISHING COMPOSITION | BASF SE (DE) | 2020-09-30 | — | — | EP | disclosed |
| US-20200299547-A1 | CHEMICAL MECHANICAL POLISHING COMPOSITION | BASF SE (DE) | 2020-09-24 | — | — | US | disclosed |
| CN-111356747-A | Chemical mechanical polishing composition | 巴斯夫欧洲公司 | 2020-06-30 | — | — | CN | disclosed |
| EP-3334794-B1 | USE OF A CHEMICAL MECHANICAL POLISHING (CMP) COMPOSITION FOR POLISHING OF COBALT COMPRISING SUBSTRATES | BASF SE (DE) | 2020-02-19 | — | — | EP | disclosed |
| WO-2019101555-A1 | CHEMICAL MECHANICAL POLISHING COMPOSITION | BASF SE (DE) | 2019-05-31 | — | — | WO | disclosed |
| US-20100022544-A1 | CYCLICALLY SUBSTITUTED 3,5-DICYANO-2-THIOPYRIDINES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-01-28 | — | — | US | disclosed |
| EP-2099788-A1 | CYCLICALLY SUBSTITUTED 3,5-DICYANO-2-THIOPYRIDINES AND USE THEREOF | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-09-16 | — | — | EP | disclosed |
| WO-2008064788-A1 | CYCLICALLY SUBSTITUTED 3,5-DICYANO-2-THIOPYRIDINES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-06-05 | — | — | WO | disclosed |
| US-6689771-B2 | TREATMENT OF RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, PERIODONTITIS, GINGIVITIS, CORNEAL ULCERATION, SOLID TUMOR GROWTH | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-02-10 | — | — | US | disclosed |
| US-6610731-B2 | Antiinflammatory | BRISTOL-MYERS SQUIBB COMPANY | 2003-08-26 | — | — | US | disclosed |
| US-6403632-B1 | CYCLIC AMIDE DERIVATIVE | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2002-06-11 | — | — | US | disclosed |
| US-6376665-B1 | ANTIARTHRITIC AGENTS, ANTIINFLAMMATORY AGENTS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-04-23 | — | — | US | disclosed |
| EP-1165500-A1 | AMIDE DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES,TNF-ALPHA,AND AGGRECANASE | Du Pont Pharmaceuticals Company (US) | 2002-01-02 | — | — | EP | disclosed |
| WO-2000059874-A1 | NOVEL AMIDE DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES, TNF-α, AND AGGRECANASE | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-10-12 | — | — | WO | disclosed |
| US-6057336-A | ANTIINFLAMMATORY AGENTS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2000-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022544-A1 | CYCLICALLY SUBSTITUTED 3,5-DICYANO-2-THIOPYRIDINES AND USE THEREOF | QDPR, TPMT, PTGIS | PRKCI 1080/4885MAP2K4 2498/4885PARP1 2923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.